Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion type Assertion NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_head.
- NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion description "[Overall, heterozygous TPMT genotypes did not predict adverse drug reactions but were significantly associated with a subgroup of patients experiencing nausea and vomiting as the predominant adverse reaction to AZA therapy (OR 5.5, 95% CI 1.4-21.3, P = 0.0206).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_provenance.
- NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion evidence source_evidence_literature NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_provenance.
- NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion SIO_000772 15167706 NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_provenance.
- NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion wasDerivedFrom befree-20150227 NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_provenance.
- NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_assertion wasGeneratedBy ECO_0000203 NP756603.RAHTsYuVMwwcj1RmOZjUd3CkxL_3UVyW7JY9986AZTnUk130_provenance.